Abstract
The traditional view that blood pressure (BP) can fundamentally be viewed as a function of cardiac output and systemic vascular resistance remains valid, although much has been learned about the many ways in which these two arms of the equation can be affected, down to the cellular level. The goal of this chapter is to provide the reader with an overview of the many pathophysiologic alterations that can lead to the development of hypertension (HTN).
This is a preview of subscription content, log in via an institution to check access.
References
Feber J, Ruzicka M, Geier P, Litwin M. Autonomic nervous system dysregulation in pediatric hypertension. Curr Hypertens Rep. 2014;16(5):426.
Mary DA, Stoker JB. The activity of single vasoconstrictor nerve units in hypertension. Acta Physiol Scand. 2003;177(3):367–76.
Julius S, Pascual AV, Sannerstedt R, Mitchell C. Relationship between cardiac output and peripheral resistance in borderline hypertension. Circulation. 1971;43(3):382–90.
Julius S. Changing role of the autonomic nervous system in human hypertension. J Hypertens Suppl. 1990;8(7):S59–65.
Mulvany MJ. The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol. 1992;19 Suppl 2:S22–7.
Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330(20):1431–8.
Vicaut E. Microcirculation and arterial hypertension. Drugs. 1999;58(Spec No 1):1–10.
Owens GK, Schwartz SM. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Role of cellular hypertrophy, hyperploidy, and hyperplasia. Circ Res. 1982;51(3):280–9.
Berk BC. Biology of the vascular wall in hypertension. In: Brenner BM, editor. Brenner and Rector’s the kidney. 6th ed. Philadelphia: W.B. Saunders; 2000. p. 1943–66.
Berk BC, Alexander RW, Brock TA, Gimbrone Jr MA, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science. 1986;232(4746):87–90.
Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62(4):749–56.
Folkow B. Structure and function of the arteries in hypertension. Am Heart J. 1987;114(4 Pt 2):938–48.
Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002;4(3):256–60.
McCrory WW, Klein AA, Rosenthal RA. Blood pressure, heart rate, and plasma catecholamines in normal and hypertensive children and their siblings at rest and after standing. Hypertension. 1982;4(4):507–13.
Goldstein DS, Lake CR, Chernow B, Ziegler MG, Coleman MD, Taylor AA, et al. Age-dependence of hypertensive-normotensive differences in plasma norepinephrine. Hypertension. 1983;5(1):100–4.
Reinhart GA, Lohmeier TE, Hord Jr CE. Hypertension induced by chronic renal adrenergic stimulation is angiotensin dependent. Hypertension. 1995;25(5):940–9.
Dubinion JH, Mi Z, Jackson EK. Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2006;317(3):1330–6.
Wong PC, Bernard R, Timmermans PB. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension. 1992;19(6 Pt 2):663–7.
Boke T, Malik KU. Enhancement by locally generated angiotensin II of release of the adrenergic transmitter in the isolated rat kidney. J Pharmacol Exp Ther. 1983;226(3):900–7.
Lurbe E, Thijs L, Redon J, Alvarez V, Tacons J, Staessen J. Diurnal blood pressure curve in children and adolescents. J Hypertens. 1996;14(1):41–6.
Seeman T, Palyzova D, Dusek J, Janda J. Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension. J Pediatr. 2005;147(3):366–71.
Martino TA, Oudit GY, Herzenberg AM, Tata N, Koletar MM, Kabir GM, et al. Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. Am J Physiol Regul Integr Comp Physiol. 2008;294(5):R1675–83.
Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23(10):645–53.
Moore RY. The suprachiasmatic nucleus and the circadian timing system. Prog Mol Biol Transl Sci. 2013;119:1–28.
Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett. 2002;23 Suppl 1:79–83.
Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85(3):335–53.
Goncharuk VD, van Heerikhuize J, Dai JP, Swaab DF, Buijs RM. Neuropeptide changes in the suprachiasmatic nucleus in primary hypertension indicate functional impairment of the biological clock. J Comp Neurol. 2001;431(3):320–30.
Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res. 2007;56(6):671–84.
Simoes ESAC, Flynn JT. The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol. 2012;27(10):1835–45.
Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87(6):1816–28.
Danser AH, Batenburg WW, van Esch JH, Krop M. Prorenin anno 2008. J Mol Med. 2008;86(6):655–8.
Batenburg WW, Danser AH. (Pro)renin and its receptors: pathophysiological implications. Clin Sci (Lond). 2012;123(3):121–33.
Muller DN, Luft FC. The renin-angiotensin system in the vessel wall. Basic Res Cardiol. 1998;93 Suppl 2:7–14.
Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med. 2008;86(6):615–21.
Robles NR, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther. 2014;19(1):14–33.
Inagami T, Guo DF, Kitami Y. Molecular biology of angiotensin II receptors: an overview. J Hypertens Suppl. 1994;12(10):S83–94.
Aguilera G, Catt K. Regulation of vascular angiotensin II receptors in the rat during altered sodium intake. Circ Res. 1981;49(3):751–8.
Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97(8):1916–23.
Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35(1 Pt 2):193–201.
Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95(3):995–1001.
Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000;58(1):251–9.
Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res. 2000;86(12):1266–72.
Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066–71.
Zhu YC, Zhu YZ, Lu N, Wang MJ, Wang YX, Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol. 2003;30(12):911–8.
Simon G. Pathogenesis of structural vascular changes in hypertension. J Hypertens. 2004;22(1):3–10.
Chandra S, Narang R, Sreenivas V, Bhatia J, Saluja D, Srivastava K. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case–control study. PLoS One. 2014;9(7):e101502.
Sugimoto K, Katsuya T, Ohkubo T, Hozawa A, Yamamoto K, Matsuo A, et al. Association between angiotensin II type 1 receptor gene polymorphism and essential hypertension: the Ohasama Study. Hypertens Res. 2004;27(8):551–6.
Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30(5):1238–46.
Ichiki T, Kambayashi Y, Inagami T. Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Circ Res. 1995;77(6):1070–6.
Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83(12):1182–91.
Savoia C, D’Agostino M, Lauri F, Volpe M. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20(2):125–32.
Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab. 2008;19(3):84–7.
DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol. 1999;10 Suppl 11:S90–4.
Ferguson AV, Washburn DL. Angiotensin II: a peptidergic neurotransmitter in central autonomic pathways. Prog Neurobiol. 1998;54(2):169–92.
Allen AM, Dampney RA, Mendelsohn FA. Angiotensin receptor binding and pressor effects in cat subretrofacial nucleus. Am J Physiol. 1988;255(5 Pt 2):H1011–7.
Kumagai H, Oshima N, Matsuura T, Iigaya K, Imai M, Onimaru H, et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res. 2012;35(2):132–41.
Saigusa T, Iriki M, Arita J. Brain angiotensin II tonically modulates sympathetic baroreflex in rabbit ventrolateral medulla. Am J Physiol. 1996;271(3 Pt 2):H1015–21.
Dampney RA, Fontes MA, Hirooka Y, Horiuchi J, Potts PD, Tagawa T. Role of angiotensin II receptors in the regulation of vasomotor neurons in the ventrolateral medulla. Clin Exp Pharmacol Physiol. 2002;29(5–6):467–72.
Song K, Allen AM, Paxinos G, Mendelsohn FA. Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol. 1992;316(4):467–84.
Bader M. ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflugers Arch Eur J Physiol. 2013;465(1):79–85.
Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension. 2003;41(4):871–3.
Wysocki J, Gonzalez-Pacheco FR, Batlle D. Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease. Curr Hypertens Rep. 2008;10(1):70–7.
Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis. Exp Physiol. 2008;93(5):519–27.
Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100(14):8258–63.
Simoes-e-Silva AC, Baracho NC, Passaglio KT, Santos RA. Renal actions of angiotensin-(1–7). Braz J Med Biol Res. 1997;30(4):503–13.
Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats. Am J Physiol Heart Circ Physiol. 2003;284(6):H1985–94.
DelliPizzi AM, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin(1–7). Br J Pharmacol. 1994;111(1):1–3.
van der Wouden EA, Ochodnicky P, van Dokkum RP, Roks AJ, Deelman LE, de Zeeuw D, et al. The role of angiotensin(1–7) in renal vasculature of the rat. J Hypertens. 2006;24(10):1971–8.
Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr Opin Pharmacol. 2008;8(2):127–32.
Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension. 2008;51(5):1259–64.
Ott C, Schneider MP, Delles C, Schlaich MP, Hilgers KF, Schmieder RE. Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. Pharmacogenet Genomics. 2011;21(6):347–9.
Reudelhuber TL. The interaction between prorenin, renin and the (pro)renin receptor: time to rethink the role in hypertension. Curr Opin Nephrol Hypertens. 2012;21(2):137–41.
Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL, et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol. 1991;5(10):1513–22.
Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension. 2000;36(4):495–500.
MacKenzie SM, Clark CJ, Fraser R, Gomez-Sanchez CE, Connell JM, Davies E. Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol. 2000;24(3):321–8.
Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005;10(1):7–13.
Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10(1):15–22.
Koenig W, Binner L, Gabrielsen F, Sund M, Rosenthal J, Hombach V. Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. J Cardiovasc Pharmacol. 1991;18(3):349–53.
Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension. 1992;19(3):270–7.
Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32(6):865–79.
Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31(1 Pt 2):451–8.
Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol. 2001;281(3):R944–50.
Susic D, Varagic J, Ahn J, Matavelli L, Frohlich ED. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol. 2007;292(1):H175–9.
Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51(2):432–9.
Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA. The dopaminergic system in hypertension. Clin Sci (Lond). 2007;112(12):583–97.
Harris RC, Zhang MZ. Dopamine, the kidney, and hypertension. Curr Hypertens Rep. 2012;14(2):138–43.
Lucas-Teixeira V, Serrao MP, Soares-Da-Silva P. Effect of salt intake on jejunal dopamine, Na+, K+-ATPase activity and electrolyte transport. Acta Physiol Scand. 2000;168(1):225–31.
Bek MJ, Eisner GM, Felder RA, Jose PA. Dopamine receptors in hypertension. Mt Sinai J Med. 2001;68(6):362–9.
Zabik JE, Sprague JE, Odio M. Interactive dopaminergic and noradrenergic systems in the regulation of thirst in the rat. Physiol Behav. 1993;54(1):29–33.
Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345(21):1548–57.
Jose PA, Eisner GM, Felder RA. Renal dopamine receptors in health and hypertension. Pharmacol Ther. 1998;80(2):149–82.
Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 1996;97(12):2745–52.
Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, et al. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest. 1998;102(3):493–8.
Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation. 1999;99(11):1407–10.
Sato M, Soma M, Nakayama T, Kanmatsuse K. Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension. 2000;36(2):183–6.
Sen S, Nesse R, Sheng L, Stoltenberg SF, Gleiberman L, Burmeister M, et al. Association between a dopamine-4 receptor polymorphism and blood pressure. Am J Hypertens. 2005;18(9 Pt 1):1206–10.
Zhu H, Lu Y, Wang X, Treiber FA, Harshfield GA, Snieder H, et al. The G protein-coupled receptor kinase 4 gene affects blood pressure in young normotensive twins. Am J Hypertens. 2006;19(1):61–6.
Staessen JA, Kuznetsova T, Zhang H, Maillard M, Bochud M, Hasenkamp S, et al. Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4. Hypertension. 2008;51(6):1643–50.
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5):321–8.
Baldini PM, De Vito P, Fraziano M, Mattioli P, Luly P, Di Nardo P. Atrial natriuretic factor inhibits mitogen-induced growth in aortic smooth muscle cells. J Cell Physiol. 2002;193(1):103–9.
Beltowski J, Wojcicka G. Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Med Sci Monit Int Med J Exp Clin Res. 2002;8(2):RA39–52.
Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78(5):1362–74.
Volpe M, Mele AF, Indolfi C, De Luca N, Lembo G, Focaccio A, et al. Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J Am Coll Cardiol. 1987;10(4):787–93.
Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab. 1996;81(11):3871–6.
Volpe M, Vecchione F, Cuocolo A, Lembo G, Pignalosa S, Condorelli M, et al. Hemodynamic responses to atrial natriuretic factor in nephrectomized rabbits: attenuation of the circulatory consequences of acute volume expansion. Circ Res. 1988;63(2):322–9.
Rutledge DR, Sun Y, Ross EA. Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens. 1995;13(9):953–5.
Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res. 2000;86(8):841–5.
Wu Q, Xu-Cai YO, Chen S, Wang W. Corin: new insights into the natriuretic peptide system. Kidney Int. 2009;75:142–6.
Xue H, Wang S, Wang H, Sun K, Song X, Zhang W, et al. Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci (Lond). 2008;114(2):131–7.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–5.
Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86(8):2863–7.
Gray GA. Generation of endothelin. In: Gray GA, Webb DJ, editors. Molecular biology and pharmacology of the endothelins. Austin: R.G. Landes; 1995. p. 13–32.
Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10(11):1379–86.
Hirata Y. Endothelin peptides. Curr Opin Nephrol Hypertens. 1996;5(1):12–5.
Miyoshi Y, Nakaya Y, Wakatsuki T, Nakaya S, Fujino K, Saito K, et al. Endothelin blocks ATP-sensitive K+ channels and depolarizes smooth muscle cells of porcine coronary artery. Circ Res. 1992;70(3):612–6.
King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol. 1989;256(6 Pt 2):F1051–8.
Zeidel ML, Brady HR, Kone BC, Gullans SR, Brenner BM. Endothelin, a peptide inhibitor of Na(+)-K(+)-ATPase in intact renaltubular epithelial cells. Am J Physiol. 1989;257(6 Pt 1):C1101–7.
Dupuis J. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can J Cardiol. 2000;16(7):903–10.
Levin ER. Endothelins. N Engl J Med. 1995;333(6):356–63.
Schiffrin EL, Lariviere R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res. 1996;33(3):235–48.
Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest. 1994;94(4):1359–64.
Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond). 1990;78(3):261–4.
Kohno M, Murakawa K, Horio T, Yokokawa K, Yasunari K, Fukui T, et al. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension. 1991;18(1):93–100.
Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1989;1(8645):991–2.
Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest. 1991;88(1):310–4.
Nambi P, Pullen M, Contino LC, Brooks DP. Upregulation of renal endothelin receptors in rats with cyclosporine A-induced nephrotoxicity. Eur J Pharmacol. 1990;187(1):113–6.
Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Takano Y, Kokado Y, et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. Transplant Proc. 1991;23(6):3133–6.
Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28(4):652–5.
Stevens PA, Brown MJ. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S9–12.
Barath A, Endreffy E, Bereczki C, Gellen B, Szucs B, Nemeth I, et al. Endothelin-1 gene and endothelial nitric oxide synthase gene polymorphisms in adolescents with juvenile and obesity-associated hypertension. Acta Physiol Hung. 2007;94(1–2):49–66.
Speed JS, Pollock DM. Endothelin, kidney disease, and hypertension. Hypertension. 2013;61(6):1142–5.
Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002–12.
Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2(8670):997–1000.
Gkaliagkousi E, Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front Biosci. 2011;16:1873–97.
Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323(1):22–7.
Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang WZ, et al. Impaired l-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004;110(24):3680–6.
Chen PY, Sanders PW. l-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991;88(5):1559–67.
Nakaki T, Hishikawa K, Suzuki H, Saruta T, Kato R. l-arginine-induced hypotension. Lancet. 1990;336(8716):696.
Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296(2):R195–200.
Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertension. 1991;17(2):117–30.
Chen YF, Li PL, Zou AP. Oxidative stress enhances the production and actions of adenosine in the kidney. Am J Physiol Regul Integr Comp Physiol. 2001;281(6):R1808–16.
Trincavelli ML, Daniele S, Martini C. Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860–77.
Welch WJ. Adenosine A1 receptor antagonists in the kidney: effects in fluid-retaining disorders. Curr Opin Pharmacol. 2002;2(2):165–70.
Koupenova M, Johnston-Cox H, Ravid K. Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors. Curr Atheroscler Rep. 2012;14(5):460–8.
Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am. 2012;96(2):257–68.
Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg. 1997;85(4):734–8.
Ertek S, Cicero AF. Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology. Arch Med Sci AMS. 2013;9(5):944–52.
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9.
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553–60.
Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett. 1994;338(1):6–10.
Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201(3):1160–6.
Cheung BM, Li CY, Wong LY. Adrenomedullin: its role in the cardiovascular system. Semin Vasc Med. 2004;4(2):129–34.
Hu W, Zhou PH, Zhang XB, Xu CG, Wang W. Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism. Endocrine. 2014; DOI: 10.1007/s12020-014-0316-9.
Letizia C, Subioli S, Cerci S, Caliumi C, Verrelli C, Delfini E, et al. High plasma adrenomedullin concentrations in patients with high-renin essential hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3(2):126–9.
Ishimitsu T, Tsukada K, Minami J, Ono H, Matsuoka H. Variations of human adrenomedullin gene and its relation to cardiovascular diseases. Hypertens Res. 2003;26(Suppl):S129–34.
Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275–80.
Desir GV, Wang L, Peixoto AJ. Human renalase: a review of its biology, function, and implications for hypertension. J Am Soc Hypertens JASH. 2012;6(6):417–26.
Quelhas-Santos J, Sampaio-Maia B, Simoes-Silva L, Serrao P, Fernandes-Cerqueira C, Soares-Silva I, et al. Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney. J Hypertens. 2013;31(3):543–52; discussion 52–3.
Desir G. Novel insights into the physiology of renalase and its role in hypertension and heart disease. Pediatr Nephrol. 2012;27(5):719–25.
Stec A, Semczuk A, Furmaga J, Ksiazek A, Buraczynska M. Polymorphism of the renalase gene in end-stage renal disease patients affected by hypertension. Nephrol Dial Transplant. 2012;27(11):4162–6.
Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. J Physiol. 2014;592(Pt 18):3955–67.
Cowley Jr AW. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol. 1997;273(1 Pt 2):R1–15.
Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R. Protective importance of the myogenic response in the renal circulation. Hypertension. 2009;54(2):393–8.
Iversen BM, Sekse I, Ofstad J. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats. Am J Physiol. 1987;252(3 Pt 2):F480–6.
Sorensen CM, Leyssac PP, Skott O, Holstein-Rathlou NH. Role of the renin-angiotensin system in regulation and autoregulation of renal blood flow. Am J Physiol Regul Integr Comp Physiol. 2000;279(3):R1017–24.
Hayashi K, Epstein M, Loutzenhiser R. Pressure-induced vasoconstriction of renal microvessels in normotensive and hypertensive rats. Studies in the isolated perfused hydronephrotic kidney. Circ Res. 1989;65(6):1475–84.
Hayashi K, Epstein M, Loutzenhiser R. Enhanced myogenic responsiveness of renal interlobular arteries in spontaneously hypertensive rats. Hypertension. 1992;19(2):153–60.
Takenaka T, Forster H, De Micheli A, Epstein M. Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res. 1992;71(2):471–80.
Almeida JB, Saragoca MA, Tavares A, Cezareti ML, Draibe SA, Ramos OL. Severe hypertension induces disturbances of renal autoregulation. Hypertension. 1992;19(2 Suppl):II279–83.
Crowley SD, Coffman TM. The inextricable role of the kidney in hypertension. J Clin Invest. 2014;124(6):2341–7.
Ruiz-Opazo N, Lopez LV, Herrera VL. The dual AngII/AVP receptor gene N119S/C163R variant exhibits sodium-induced dysfunction and cosegregates with salt-sensitive hypertension in the Dahl salt-sensitive hypertensive rat model. Mol Med. 2002;8(1):24–32.
Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci U S A. 1998;95(24):14552–7.
Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest. 1999;104(7):R19–23.
Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005;85(2):679–715.
Arar MY, Hogg RJ, Arant Jr BS, Seikaly MG. Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol. 1994;8(2):186–9.
Robinson RF, Batisky DL, Hayes JR, Nahata MC, Mahan JD. Body mass index in primary and secondary pediatric hypertension. Pediatr Nephrol. 2004;19(12):1379–84.
Flynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol. 2005;20(7):961–6.
Kapur G, Ahmed M, Pan C, Mitsnefes M, Chiang M, Mattoo TK. Secondary hypertension in overweight and stage 1 hypertensive children: a Midwest Pediatric Nephrology Consortium report. J Clin Hypertens (Greenwich). 2010;12(1):34–9.
Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488–96.
Flynn J. The changing face of pediatric hypertension in the era of the childhood obesity epidemic. Pediatr Nephrol. 2013;28(7):1059–66.
Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, et al. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension. 1995;26(6 Pt 1):919–24.
Schneider GM, Jacobs DW, Gevirtz RN, O’Connor DT. Cardiovascular haemodynamic response to repeated mental stress in normotensive subjects at genetic risk of hypertension: evidence of enhanced reactivity, blunted adaptation, and delayed recovery. J Hum Hypertens. 2003;17(12):829–40.
Longini Jr IM, Higgins MW, Hinton PC, Moll PP, Keller JB. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epidemiol. 1984;120(1):131–44.
Mongeau JG. Heredity and blood pressure in humans: an overview. Pediatr Nephrol. 1987;1(1):69–75.
Lifton RP. Genetic determinants of human hypertension. Proc Natl Acad Sci U S A. 1995;92(19):8545–51.
Jeunemaitre X, Gimenez-Roqueplo AP, Celerier J, Corvol P. Angiotensinogen variants and human hypertension. Curr Hypertens Rep. 1999;1(1):31–41.
Watt GC, Harrap SB, Foy CJ, Holton DW, Edwards HV, Davidson HR, et al. Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure. J Hypertens. 1992;10(5):473–82.
Williams SM, Addy JH, Phillips 3rd JA, Dai M, Kpodonu J, Afful J, et al. Combinations of variations in multiple genes are associated with hypertension. Hypertension. 2000;36(1):2–6.
Binder A. A review of the genetics of essential hypertension. Curr Opin Cardiol. 2007;22(3):176–84.
Zhao Q, Kelly TN, Li C, He J. Progress and future aspects in genetics of human hypertension. Curr Hypertens Rep. 2013;15(6):676–86.
Law CM, Barker DJ, Bull AR, Osmond C. Maternal and fetal influences on blood pressure. Arch Dis Child. 1991;66(11):1291–5.
Zureik M, Bonithon-Kopp C, Lecomte E, Siest G, Ducimetiere P. Weights at birth and in early infancy, systolic pressure, and left ventricular structure in subjects aged 8 to 24 years. Hypertension. 1996;27(3 Pt 1):339–45.
Barker DJ, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002;31(6):1235–9.
Hofman PL, Cutfield WS. Insulin sensitivity in people born pre-term, with low or very low birth weight and small for gestational age. J Endocrinol Invest. 2006;29(1 Suppl):2–8.
Siewert-Delle A, Ljungman S. The impact of birth weight and gestational age on blood pressure in adult life: a population-based study of 49-year-old men. Am J Hypertens. 1998;11(8 Pt 1):946–53.
Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993;341(8850):938–41.
Mackenzie HS, Lawler EV, Brenner BM. Congenital oligonephropathy: the fetal flaw in essential hypertension? Kidney Int Suppl. 1996;55:S30–4.
Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348(2):101–8.
Beratis NG, Panagoulias D, Varvarigou A. Increased blood pressure in neonates and infants whose mothers smoked during pregnancy. J Pediatr. 1996;128(6):806–12.
Singhal A, Cole TJ, Lucas A. Early nutrition in preterm infants and later blood pressure: two cohorts after randomised trials. Lancet. 2001;357(9254):413–9.
Langley-Evans SC. Critical differences between two low protein diet protocols in the programming of hypertension in the rat. Int J Food Sci Nutr. 2000;51(1):11–7.
Woods LL, Ingelfinger JR, Nyengaard JR, Rasch R. Maternal protein restriction suppresses the newborn renin-angiotensin system and programs adult hypertension in rats. Pediatr Res. 2001;49(4):460–7.
Alwasel SH, Kaleem I, Sahajpal V, Ashton N. Maternal protein restriction reduces angiotensin II AT(1) and AT(2) receptor expression in the fetal rat kidney. Kidney Blood Press Res. 2010;33(4):251–9.
Ingelfinger JR, Woods LL. Perinatal programming, renal development, and adult renal function. Am J Hypertens. 2002;15(2 Pt 2):46S–9.
Edvardsson VO, Steinthorsdottir SD, Eliasdottir SB, Indridason OS, Palsson R. Birth weight and childhood blood pressure. Curr Hypertens Rep. 2012;14(6):596–602.
Hemachandra AH, Howards PP, Furth SL, Klebanoff MA. Birth weight, postnatal growth, and risk for high blood pressure at 7 years of age: results from the Collaborative Perinatal Project. Pediatrics. 2007;119(6):e1264–70.
Belfort MB, Rifas-Shiman SL, Rich-Edwards J, Kleinman KP, Gillman MW. Size at birth, infant growth, and blood pressure at three years of age. J Pediatr. 2007;151(6):670–4.
Filler G, Yasin A, Kesarwani P, Garg AX, Lindsay R, Sharma AP. Big mother or small baby: which predicts hypertension? J Clin Hypertens (Greenwich). 2011;13(1):35–41.
Williams Jr DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt BV. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun. 1991;175(2):556–61.
Johansson-Kark M, Rasmussen F, De Stavola B, Leon DA. Fetal growth and systolic blood pressure in young adulthood: the Swedish Young Male Twins Study. Paediatr Perinat Epidemiol. 2002;16(3):200–9.
Falkner B, Kushner H, Onesti G, Angelakos ET. Cardiovascular characteristics in adolescents who develop essential hypertension. Hypertension. 1981;3(5):521–7.
Voors AW, Webber LS, Berenson GS. Resting heart rate and pressure-rate product of children in a total biracial community: the Bogalusa Heart Study. Am J Epidemiol. 1982;116(2):276–86.
Palatini P, Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep. 2009;11(3):199–205.
Menkes MS, Matthews KA, Krantz DS, Lundberg U, Mead LA, Qaqish B, et al. Cardiovascular reactivity to the cold pressor test as a predictor of hypertension. Hypertension. 1989;14(5):524–30.
Treiber FA, McCaffrey F, Musante L, Rhodes T, Davis H, Strong WB, et al. Ethnicity, family history of hypertension and patterns of hemodynamic reactivity in boys. Psychosom Med. 1993;55(1):70–7.
Muller R, Steffen HM, Weller P, Krone W. Plasma catecholamines and adrenoceptors in young hypertensive patients. J Hum Hypertens. 1994;8(5):351–5.
Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997;10(1):77–83.
Lopes HF, Silva HB, Consolim-Colombo FM, Barreto Filho JA, Riccio GM, Giorgi DM, et al. Autonomic abnormalities demonstrable in young normotensive subjects who are children of hypertensive parents. Braz J Med Biol Res. 2000;33(1):51–4.
Zhu H, Poole J, Lu Y, Harshfield GA, Treiber FA, Snieder H, et al. Sympathetic nervous system, genes and human essential hypertension. Curr Neurovasc Res. 2005;2(4):303–17.
Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14(2):177–83.
Victor RG, Shafiq MM. Sympathetic neural mechanisms in human hypertension. Curr Hypertens Rep. 2008;10(3):241–7.
Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E, et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50(5):862–8.
Grassi G, Seravalle G, Dell’Oro R, Mancia G. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep. 2011;13(4):303–8.
Koch VH, Furusawa EA, Saito MI, Colli A, Ignes EC, Okay Y, et al. White coat hypertension in adolescents. Clin Nephrol. 1999;52(5):297–303.
Neumann SA, Jennings JR, Muldoon MF, Manuck SB. White-coat hypertension and autonomic nervous system dysregulation. Am J Hypertens. 2005;18(5 Pt 1):584–8.
Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19(3 Pt 2):523–8.
Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:129–52.
Das UN, Repossi G, Dain A, Eynard AR. Is insulin resistance a disorder of the brain? Front Biosci. 2011;16:1–12.
Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413–37.
Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33(1):54–65.
Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14(6 Pt 2):103S–15.
Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100(2):270–8.
da Silva AA, Kuo JJ, Hall JE. Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension. 2004;43(6):1312–7.
Rahmouni K. Obesity, sympathetic overdrive, and hypertension: the leptin connection. Hypertension. 2010;55(4):844–5.
Gunduz Z, Dursun N, Akgun H, Ozturk F, Okur H, Koc N. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. Regul Pept. 2005;132(1–3):59–66.
Shatat IF, Flynn JT. Relationships between renin, aldosterone, and 24-hour ambulatory blood pressure in obese adolescents. Pediatr Res. 2011;69(4):336–40.
Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26(5):831–43.
Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129–39.
Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003;14(6):561–6.
Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–9.
Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J. 2006;70(11):1437–42.
Warolin J, Coenen KR, Kantor JL, Whitaker LE, Wang L, Acra SA, et al. The relationship of oxidative stress, adiposity and metabolic risk factors in healthy Black and White American youth. Pediatr Obes. 2014;9(1):43–52.
Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625–33.
Hunley TE, Ma LJ, Kon V. Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens. 2010;19(3):227–34.
Gupta AK, Clark RV, Kirchner KA. Effects of insulin on renal sodium excretion. Hypertension. 1992;19(1 Suppl):I78–82.
Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens. 2001;14(11 Pt 2):304S–9.
Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580–5.
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87(6):2246–52.
Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334(6):374–81.
Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990;85(6):1844–52.
Bornfeldt KE, Arnqvist HJ, Capron L. In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia. 1992;35(2):104–8.
Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens. 2009;22(1):106–11.
Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension. 1990;16(6):706–11.
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275(9):457–64.
Prebis JW, Gruskin AB, Polinsky MS, Baluarte HJ. Uric acid in childhood essential hypertension. J Pediatr. 1981;98(5):702–7.
Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45(1):28–33.
Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006;48(6):1037–42.
Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18(1):287–92.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991–7.
Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C, et al. Effects of acute and chronic l-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol. 2007;292(4):F1238–44.
Gruskin AB. The adolescent with essential hypertension. Am J Kidney Dis. 1985;6(2):86–90.
Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247–52.
Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17(5):1466–71.
Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94(7):932–5.
Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32.
Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006;62:633–44.
Weinberger MH, Miller JZ, Luft FC, et al. Sodium and blood pressure: an overview. In: Children’s blood pressure: report of the 88th Ross Conference on pediatric research. Columbus: Ross Laboratories; 1985. p. 77–85.
Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I–Analysis of observational data among populations. BMJ. 1991;302(6780):811–5.
He FJ, MacGregor GA. Potassium intake and blood pressure. Am J Hypertens. 1999;12(8 Pt 1):849–51.
Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(2 Suppl):643S–51.
Simons-Morton DG, Obarzanek E. Diet and blood pressure in children and adolescents. Pediatr Nephrol. 1997;11(2):244–9.
Grimm Jr RH, Neaton JD, Elmer PJ, Svendsen KH, Levin J, Segal M, et al. The influence of oral potassium chloride on blood pressure in hypertensive men on a low-sodium diet. N Engl J Med. 1990;322(9):569–74.
He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open. 2014;4(4):e004549.
Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117–24.
Couch SC, Saelens BE, Levin L, Dart K, Falciglia G, Daniels SR. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. J Pediatr. 2008;152(4):494–501.
Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27(3 Pt 2):481–90.
Simonetti GD, Raio L, Surbek D, Nelle M, Frey FJ, Mohaupt MG. Salt sensitivity of children with low birth weight. Hypertension. 2008;52:625–30.
Harshfield GA, Dong Y, Kapuku GK, Zhu H, Hanevold CD. Stress-induced sodium retention and hypertension: a review and hypothesis. Curr Hypertens Rep. 2009;11(1):29–34.
Berenson GS, Chen W, Dasmahapatra P, Fernandez C, Giles T, Xu J, et al. Stimulus response of blood pressure in black and white young individuals helps explain racial divergence in adult cardiovascular disease: the Bogalusa Heart Study. J Am Soc Hypertens JASH. 2011;5(4):230–8.
Pickering TG. The effects of environmental and lifestyle factors on blood pressure and the intermediary role of the sympathetic nervous system. J Hum Hypertens. 1997;11 Suppl 1:S9–18.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104(4):545–56.
Ingelfinger JR. The molecular basis of pediatric hypertension. Pediatr Clin North Am. 2006;53(5):1011–28, x–xi.
Simonetti GD, Mohaupt MG, Bianchetti MG. Monogenic forms of hypertension. Eur J Pediatr. 2012;171(10):1433–9.
Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2(1):66–74.
Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355(6357):262–5.
Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, et al. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet. 2000;37(11):831–5.
New MI, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. Trends Endocrinol Metab. 2005;16(3):92–7.
Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117–23.
Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768–72.
Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289(5476):119–23.
Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10(4):394–9.
Funder JW. Adrenal steroids: new answers, new questions. Science. 1987;237(4812):236–7.
Bailey MA, Paterson JM, Hadoke PW, Wrobel N, Bellamy CO, Brownstein DG, et al. A switch in the mechanism of hypertension in the syndrome of apparent mineralocorticoid excess. J Am Soc Nephrol. 2008;19(1):47–58.
Stowasser M, Gordon RD. Monogenic mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab. 2006;20(3):401–20.
Vehaskari VM. Heritable forms of hypertension. Pediatr Nephrol. 2009;24:1929–37.
Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann N Y Acad Sci. 2004;1024:168–81.
Chrousos GP, Loriaux DL, Brandon D, Tomita M, Vingerhoeds AC, Merriam GR, et al. Primary cortisol resistance: a familial syndrome and an animal model. J Steroid Biochem. 1983;19(1B):567–75.
Vingerhoeds AC, Thijssen JH, Schwarz F. Spontaneous hypercortisolism without Cushing’s syndrome. J Clin Endocrinol Metab. 1976;43(5):1128–33.
Liddle GW, Bledsoe T, Coppage Jr WS. Hypertension reviews. J Tenn Med Assoc. 1974;67(8):669.
Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle’s syndrome revisited–a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994;330(3):178–81.
Shimkets RA, Lifton RP, Canessa CM. The activity of the epithelial sodium channel is regulated by clathrin-mediated endocytosis. J Biol Chem. 1997;272(41):25537–41.
Furuhashi M, Kitamura K, Adachi M, Miyoshi T, Wakida N, Ura N, et al. Liddle’s syndrome caused by a novel mutation in the proline-rich PY motif of the epithelial sodium channel beta-subunit. J Clin Endocrinol Metab. 2005;90(1):340–4.
Snyder PM, Price MP, McDonald FJ, Adams CM, Volk KA, Zeiher BG, et al. Mechanism by which Liddle’s syndrome mutations increase activity of a human epithelial Na+ channel. Cell. 1995;83(6):969–78.
Kamynina E, Staub O. Concerted action of ENaC, Nedd4-2, and Sgk1 in transepithelial Na(+) transport. Am J Physiol Renal Physiol. 2002;283(3):F377–87.
Hannila-Handelberg T, Kontula K, Tikkanen I, Tikkanen T, Fyhrquist F, Helin K, et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med Genet. 2005;6:4.
Swift PA, Macgregor GA. Genetic variation in the epithelial sodium channel: a risk factor for hypertension in people of African origin. Adv Ren Replace Ther. 2004;11(1):76–86.
Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995;11(1):76–82.
Williams SS. Advances in genetic hypertension. Curr Opin Pediatr. 2007;19(2):192–8.
Staub O, Verrey F. Impact of Nedd4 proteins and serum and glucocorticoid-induced kinases on epithelial Na+ transport in the distal nephron. J Am Soc Nephrol. 2005;16(11):3167–74.
Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust. 1964;2:305–6.
Gordon RD. The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon’s syndrome. Aust N Z J Med. 1986;16(2):183–4.
Take C, Ikeda K, Kurasawa T, Kurokawa K. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N Engl J Med. 1991;324(7):472–6.
Erdogan G, Corapcioglu D, Erdogan MF, Hallioglu J, Uysal AR. Furosemide and dDAVP for the treatment of pseudohypoaldosteronism type II. J Endocrinol Invest. 1997;20(11):681–4.
Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293(5532):1107–12.
Disse-Nicodeme S, Achard JM, Desitter I, Houot AM, Fournier A, Corvol P, et al. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet. 2000;67(2):302–10.
Mansfield TA, Simon DB, Farfel Z, Bia M, Tucci JR, Lebel M, et al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet. 1997;16(2):202–5.
Cope G, Golbang A, O’Shaughnessy KM. WNK kinases and the control of blood pressure. Pharmacol Ther. 2005;106(2):221–31.
Golbang AP, Murthy M, Hamad A, Liu CH, Cope G, Van’t Hoff W, et al. A new kindred with pseudohypoaldosteronism type II and a novel mutation (564D > H) in the acidic motif of the WNK4 gene. Hypertension. 2005;46(2):295–300.
Huang CL, Kuo E. Mechanisms of disease: WNK-ing at the mechanism of salt-sensitive hypertension. Nat Clin Pract Nephrol. 2007;3(11):623–30.
Huang CL, Kuo E, Toto RD. WNK kinases and essential hypertension. Curr Opin Nephrol Hypertens. 2008;17(2):133–7.
Schuster H, Wienker TF, Toka HR, Bahring S, Jeschke E, Toka O, et al. Autosomal dominant hypertension and brachydactyly in a Turkish kindred resembles essential hypertension. Hypertension. 1996;28(6):1085–92.
Bilginturan N, Zileli S, Karacadag S, Pirnar T. Hereditary brachydactyly associated with hypertension. J Med Genet. 1973;10(3):253–9.
Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402(6764):880–3.
Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, et al. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 2004;306(5699):1190–4.
Nystrom HC, Jia J, Johansson M, Lambert G, Bergstrom G. Neurohormonal influences on maintenance and reversal of two-kidney one-clip renal hypertension. Acta Physiol Scand. 2002;175(3):245–51.
Nakada T, Kubota Y, Suzuki H, Sasagawa I, Watanabe M, Ishigooka M. Suppression of sympathetic nervous system attenuates the development of two-kidney, one-clip Goldblatt hypertension. J Urol. 1996;156(4):1480–4.
Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation. 1999;99(19):2537–42.
Imanishi M, Akabane S, Takamiya M, Kawamura M, Matsushima Y, Kuramochi M, et al. Critical degree of renal arterial stenosis that causes hypertension in dogs. Angiology. 1992;43(10):833–42.
Brown JJ, Davies DL, Morton JJ, Robertson JI, Cuesta V, Lever AF, et al. Mechanism of renal hypertension. Lancet. 1976;1(7971):1219–21.
Eng E, Veniant M, Floege J, Fingerle J, Alpers CE, Menard J, et al. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens. 1994;7(2):177–85.
Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346(25):1954–62.
Tullus K, Brennan E, Hamilton G, Lord R, McLaren CA, Marks SD, et al. Renovascular hypertension in children. Lancet. 2008;371(9622):1453–63.
Vo NJ, Hammelman BD, Racadio JM, Strife CF, Johnson ND, Racadio JM. Anatomic distribution of renal artery stenosis in children: implications for imaging. Pediatr Radiol. 2006;36(10):1032–6.
Rushton AR. The genetics of fibromuscular dysplasia. Arch Intern Med. 1980;140(2):233–6.
Bofinger A, Hawley C, Fisher P, Daunt N, Stowasser M, Gordon R. Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. J Hum Hypertens. 2001;15(3):185–90.
Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr. 1999;29(4):431–7.
Rose C, Wessel A, Pankau R, Partsch CJ, Bursch J. Anomalies of the abdominal aorta in Williams-Beuren syndrome–another cause of arterial hypertension. Eur J Pediatr. 2001;160(11):655–8.
NAPRTCS. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2008 Annual Report 2008.
Wuhl E, Hadtstein C, Mehls O, Schaefer F, Escape Trial G. Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure. Pediatr Res. 2004;55(3):492–7.
Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, et al. Blood pressure in children with chronic kidney disease. A report from the Chronic Kidney Disease in Children study. Hypertension. 2008;52:631–7.
VanDeVoorde RG, Mitsnefes MM. Hypertension and CKD. Adv Chronic Kidney Dis. 2011;18(5):355–61.
Alvarez-Lara MA, Martin-Malo A, Espinosa M, Rodriguez-Benot A, Aljama P. Blood pressure and body water distribution in chronic renal failure patients. Nephrol Dial Transplant. 2001;16 Suppl 1:94–7.
Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323(16):1091–6.
Boero R, Pignataro A, Ferro M, Quarello F. Sympathetic nervous system and chronic renal failure. Clin Exp Hypertens. 2001;23(1–2):69–75.
Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl. 2001;78:S14–8.
Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001;60(3):1077–82.
Vajo Z, Moffitt RA, Parvathala S, Szekacs B, Dachman WD. Elevated endothelin-1 levels and persistent stage IV hypertension in a nonvolume overloaded anephric patient. Am J Hypertens. 1996;9(9):935–7.
Van Geet C, Van Damme-Lombaerts R, Vanrusselt M, de Mol A, Proesmans W, Vermylen J. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link? Thromb Haemost. 1990;64(1):7–10.
Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol. 2008;23(3):363–71.
Mitsnefes MM, Knilans T, Mays W, Khoury PR, Daniels SR. Blood pressure and total peripheral resistance in children with chronic kidney disease. Pediatr Nephrol. 2005;20(6):803–6.
Hasegawa K, Matsushita Y, Inoue T, Morii H, Ishibashi M, Yamaji T. Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab. 1986;63(4):819–22.
Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996;28(1 Suppl 1):S56–62.
Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572–5.
London G, Guerin A, Pannier B, Marchais S, Benetos A, Safar M. Increased systolic pressure in chronic uremia. Role of arterial wave reflections. Hypertension. 1992;20(1):10–9.
Portaluppi F, Smolensky M. Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In: White WB, editor. Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa: Humana Press; 2001. p. 79–138.
NAPRTCS. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2011 Annual Report 2011. Available from https://web.emmes.com/study/ped/
Halbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr. 2012;160(4):621–5.e1.
Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JA, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 2002;61(1):266–75.
Lameire N, Van Biesen W. Importance of blood pressure and volume control in peritoneal dialysis patients. Perit Dial Int. 2001;21(2):206–11.
Rahman M, Smith MC. Hypertension in hemodialysis patients. Curr Hypertens Rep. 2001;3(6):496–502.
Erkan E, Devarajan P, Kaskel F. Role of nitric oxide, endothelin-1, and inflammatory cytokines in blood pressure regulation in hemodialysis patients. Am J Kidney Dis. 2002;40(1):76–81.
Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens. 2001;10(5):633–7.
Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4(2):470–80.
Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 1991;39(2):259–65.
Agarwal R, Lewis R, Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis. 2001;38(6):1245–50.
Baluarte HJ, Gruskin AB, Ingelfinger JR, Stablein D, Tejani A. Analysis of hypertension in children post renal transplantation–a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol. 1994;8(5):570–3.
Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol. 2003;14(10):2618–22.
Tejani AH, Sullivan EK, Harmon WE, Fine RN, Kohaut E, Emmett L, et al. Pediatric renal transplantation – the NAPRTCS experience. Clin Transpl. 1997:87–100.
NAPRTCS. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2002 Annual Report Potomac, MD 2007. Available from http://www.naprtcs.org
Seeman T. Ambulatory blood pressure monitoring in pediatric renal transplantation. Curr Hypertens Rep. 2012;14(6):608–18.
Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999;58(6):1011–27.
Mitsnefes MM. Hypertension and end-organ damage in pediatric renal transplantation. Pediatr Transplant. 2004;8(4):394–9.
Seeman T. Hypertension after renal transplantation. Pediatr Nephrol. 2009;24:959–72.
Flynn JT. Ambulatory blood pressure monitoring should be routinely performed after pediatric renal transplantation. Pediatr Transplant. 2012;16(6):533–6.
Park JB, Schiffrin EL. Effects of antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Rep. 2000;2(3):280–8.
Broyer M, Guest G, Gagnadoux MF, Beurton D. Hypertension following renal transplantation in children. Pediatr Nephrol. 1987;1(1):16–21.
Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep. 2001;3(5):434–9.
Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension. 1995;26(6 Pt 1):932–6.
Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis. 1996;27(1):151–61.
Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323(11):693–9.
Esteva-Font C, Ars E, Guillen-Gomez E, Campistol JM, Sanz L, Jimenez W, et al. Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant. 2007;22(10):2810–6.
Kramer BK, Zulke C, Kammerl MC, Schmidt C, Hengstenberg C, Fischereder M, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant. 2003;3(8):982–7.
Chapman JR, O’Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16(10):3015–26.
Audard V, Matignon M, Hemery F, Snanoudj R, Desgranges P, Anglade MC, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant. 2006;6(1):95–9.
Pouria S, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. QJM. 1998;91(3):185–9.
Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial. 2005;18(6):505–10.
Laskow DA, Curtis JJ. Post-transplant hypertension. Am J Hypertens. 1990;3(9):721–5.
Luke RG. Pathophysiology and treatment of posttransplant hypertension. J Am Soc Nephrol. 1991;2(2 Suppl 1):S37–44.
Ross RD, Clapp SK, Gunther S, Paridon SM, Humes RA, Farooki ZQ, et al. Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. Am Heart J. 1992;123(5):1293–9.
Choy M, Rocchini AP, Beekman RH, Rosenthal A, Dick M, Crowley D, et al. Paradoxical hypertension after repair of coarctation of the aorta in children: balloon angioplasty versus surgical repair. Circulation. 1987;75(6):1186–91.
O’Sullivan JJ, Derrick G, Darnell R. Prevalence of hypertension in children after early repair of coarctation of the aorta: a cohort study using casual and 24 hour blood pressure measurement. Heart. 2002;88(2):163–6.
Heger M, Willfort A, Neunteufl T, Rosenhek R, Gabriel H, Wollenek G, et al. Vascular dysfunction after coarctation repair is related to the age at surgery. Int J Cardiol. 2005;99(2):295–9.
Kenny D, Polson JW, Martin RP, Caputo M, Wilson DG, Cockcroft JR, et al. Relationship of aortic pulse wave velocity and baroreceptor reflex sensitivity to blood pressure control in patients with repaired coarctation of the aorta. Am Heart J. 2011;162(2):398–404.
De Bruno MP, Turoni CMJ, Maranon RO, Reynoso HA, Coviello A. Structural changes in the kidney induced by coarctation hypertension. Clin Exp Hypertens. 2001;23(6):501–11.
Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis. 1994;24(1):130–41.
Fountoulakis S, Tsatsoulis A. Molecular genetic aspects and pathophysiology of endocrine hypertension. Hormones (Athens). 2006;5(2):90–106.
Fonseca V, Bouloux PM. Phaeochromocytoma and paraganglioma. Baillieres Clin Endocrinol Metab. 1993;7(2):509–44.
Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1993;329(21):1531–8.
Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.
Pawlu C, Bausch B, Reisch N, Neumann HP. Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol (Paris). 2005;66(3):178–85.
Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994;6(1):70–4.
Latif F, Duh FM, Gnarra J, Tory K, Kuzmin I, Yao M, et al. von Hippel-Lindau syndrome: cloning and identification of the plasma membrane Ca(++)-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res. 1993;53(4):861–7.
Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet. 2001;357(9263):1181–2.
Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(1):49–54.
Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848–51.
Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827–36.
Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86(11):5210–6.
Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26(3):268–70.
Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304(23):2611–9.
Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43(7):663–7.
Lim PO, MacDonald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol (Oxf). 2003;59(4):427–30.
Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens. 2008;26(4):613–21.
Conn JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med. 1956;97(2):135–44.
Stewart PM. Mineralocorticoid hypertension. Lancet. 1999;353(9161):1341–7.
Schlaich MP, Klingbeil A, Hilgers K, Schobel HP, Schmieder RE. Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am Heart J. 1999;138(5 Pt 1):810–7.
Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19(9):1371–6.
Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension. 1992;19(6 Pt 1):567–74.
Gomez-Sanchez CE. Cushing’s syndrome and hypertension. Hypertension. 1986;8(3):258–64.
Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol. 1992;43(5):409–13.
Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension. 1994;23(1):25–30.
Kornel L, Manisundaram B, Nelson WA. Glucocorticoids regulate Na+ transport in vascular smooth muscle through the glucocorticoid receptor-mediated mechanism. Am J Hypertens. 1993;6(9):736–44.
Krakoff L, Nicolis G, Amsel B. Pathogenesis of hypertension in Cushing’s syndrome. Am J Med. 1975;58(2):216–20.
Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001;86(7):2929–34.
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41(1):95–102.
Moller J, Jorgensen JO, Moller N, Hansen KW, Pedersen EB, Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab. 1991;72(4):768–72.
Moller J, Nielsen S, Hansen TK. Growth hormone and fluid retention. Horm Res. 1999;51 Suppl 3:116–20.
Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54(2):137–54.
Kamide K, Hori MT, Zhu JH, Takagawa Y, Barrett JD, Eggena P, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens. 2000;18(8):1051–6.
Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem. 2001;276(25):22892–900.
Nilsson IL, Rastad J, Johansson K, Lind L. Endothelial vasodilatory function and blood pressure response to local and systemic hypercalcemia. Surgery. 2001;130(6):986–90.
Sangal AK, Kevwitch M, Rao DS, Rival J. Hypomagnesemia and hypertension in primary hyperparathyroidism. South Med J. 1989;82(9):1116–8.
Montenegro J, Gonzalez O, Saracho R, Aguirre R, Martinez I. Changes in renal function in primary hypothyroidism. Am J Kidney Dis. 1996;27(2):195–8.
Fletcher AK, Weetman AP. Hypertension and hypothyroidism. J Hum Hypertens. 1998;12(2):79–82.
Klein I, Levey GS. The cardiovascular system in thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner and Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott, Williams and Wilkins; 2000. p. 596–604.
Conn JW, Cohen EL, Lucas CP, McDonald WJ, Mayor GH, Blough Jr WM, et al. Primary reninism. Hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors. Arch Intern Med. 1972;130(5):682–96.
Friedman K, Hutchinson J, Mihora D, Kumar S, Frieder R, Sances A. Effect of roof strength in injury mitigation during pole impact. Biomed Sci Instrum. 2007;43:69–74.
Contreras F, Rivera M, Vasquez J, De la Parte MA, Velasco M. Diabetes and hypertension physiopathology and therapeutics. J Hum Hypertens. 2000;14 Suppl 1:S26–31.
Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403–18.
Nosadini R, Sambataro M, Thomaseth K, Pacini G, Cipollina MR, Brocco E, et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int. 1993;44(1):139–46.
Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond). 2007;112(7):375–84.
Smets K, Vanhaesebrouck P. Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease. Eur J Pediatr. 1996;155(7):573–5.
Anderson AH, Warady BA, Daily DK, Johnson JA, Thomas MK. Systemic hypertension in infants with severe bronchopulmonary dysplasia: associated clinical factors. Am J Perinatol. 1993;10(3):190–3.
Alagappan A, Malloy MH. Systemic hypertension in very low-birth weight infants with bronchopulmonary dysplasia: incidence and risk factors. Am J Perinatol. 1998;15(1):3–8.
Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB, Dempsey J. Sleep apnea and hypertension. A population-based study. Ann Intern Med. 1994;120(5):382–8.
Morgan BJ. Vascular consequences of intermittent hypoxia. Adv Exp Med Biol. 2007;618:69–84.
Enright PL, Goodwin JL, Sherrill DL, Quan JR, Quan SF. Blood pressure elevation associated with sleep-related breathing disorder in a community sample of white and Hispanic children: the Tucson Children’s Assessment of Sleep Apnea study. Arch Pediatr Adolesc Med. 2003;157(9):901–4.
Marcus CL, Greene MG, Carroll JL. Blood pressure in children with obstructive sleep apnea. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1098–103.
Lam JC, Ip MS. An update on obstructive sleep apnea and the metabolic syndrome. Curr Opin Pulm Med. 2007;13(6):484–9.
Krassioukov AV, Karlsson AK, Wecht JM, Wuermser LA, Mathias CJ, Marino RJ, et al. Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment. J Rehabil Res Dev. 2007;44(1):103–12.
Yamamoto K, Sobue G, Iwase S, Nagamatsu M, Mano T, Mitsuma T. Skin sympathetic nerve activity in Guillain-Barre syndrome: a microneurographic study. J Neurol Neurosurg Psychiatry. 1997;63(4):537–41.
Okada T, Hiyoshi K, Noto N, Fujita Y, Fuchigami T, Okubo O, et al. A case of Guillain-Barre syndrome accompanied by sympathetic overactivity and hypertensive encephalopathy. Acta Paediatr. 1996;85(8):1006–8.
Gitlow SE, Bertani LM, Wilk E, Li BL, Dziedzic S. Excretion of catecholamine metabolites by children with familial dysautonomia. Pediatrics. 1970;46(4):513–22.
Bell GM. Intracranial disorders and hypertension. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York: Raven; 1995. p. 2451–8.
Plets C. Arterial hypertension in neurosurgical emergencies. Am J Cardiol. 1989;63(6):40C–2.
Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension. 2003;41(3):437–45.
Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785–99.
Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol. 1997;37(3):240–9.
Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens. 2001;14(6 Pt 2):178S–85.
Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc Hypertens JASH. 2010;4(2):68–78.
Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab. 1990;71(6):1675–7.
Wang Y, Walsh SW, Kay HH. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preeclampsia. Am J Obstet Gynecol. 1992;167(4 Pt 1):946–9.
Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract. 2007;106(2):c72–81.
Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294(2):H541–50.
LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension. 2008;51(4):982–8.
Yallampalli C, Garfield RE. Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol. 1993;169(5):1316–20.
Molnar M, Suto T, Toth T, Hertelendy F. Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol. 1994;170(5 Pt 1):1458–66.
Loke YW, King A. Immunology of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(5):827–37.
Pincomb GA, Lovallo WR, Passey RB, Whitsett TL, Silverstein SM, Wilson MF. Effects of caffeine on vascular resistance, cardiac output and myocardial contractility in young men. Am J Cardiol. 1985;56(1):119–22.
Evoniuk G, von Borstel RW, Wurtman RJ. Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl)theophylline. J Pharmacol Exp Ther. 1987;240(2):428–32.
Nzerue CM, Hewan-Lowe K, Riley Jr LJ. Cocaine and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am J Kidney Dis. 2000;35(5):783–95.
Berman JA, Setty A, Steiner MJ, Kaufman KR, Skotzko C. Complicated hypertension related to the abuse of ephedrine and caffeine alkaloids. J Addict Dis. 2006;25(3):45–8.
Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33(5):821–8.
Di Gennaro C, Barilli A, Giuffredi C, Gatti C, Montanari A, Vescovi PP. Sodium sensitivity of blood pressure in long-term detoxified alcoholics. Hypertension. 2000;35(4):869–74.
Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69 Suppl 1:SI53–8.
Oelkers W, Schoneshofer M, Blumel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab. 1974;39(5):882–90.
McAreavey D, Cumming AM, Boddy K, Brown JJ, Fraser R, Leckie BJ, et al. The renin-angiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestagen oral contraceptives. Clin Endocrinol (Oxf). 1983;18(2):111–8.
Narkiewicz K, van de Borne PJ, Hausberg M, Cooley RL, Winniford MD, Davison DE, et al. Cigarette smoking increases sympathetic outflow in humans. Circulation. 1998;98(6):528–34.
Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334(3):150–4.
Liang YL, Shiel LM, Teede H, Kotsopoulos D, McNeil J, Cameron JD, et al. Effects of blood pressure, smoking, and their interaction on carotid artery structure and function. Hypertension. 2001;37(1):6–11.
Mansoor GA. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens. 2001;14(9 Pt 1):971–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Yamaguchi, I., Flynn, J.T. (2014). Pathophysiology of Hypertension. In: Avner, E., Harmon, W., Niaudet, P., Yoshikawa, N., Emma, F., Goldstein, S. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27843-3_55-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-27843-3_55-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27843-3
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Pathophysiology and Epidemiology of Hypertension in Children- Published:
- 31 August 2021
DOI: https://doi.org/10.1007/978-3-642-27843-3_55-2
-
Original
Pathophysiology of Hypertension- Published:
- 03 December 2014
DOI: https://doi.org/10.1007/978-3-642-27843-3_55-1